The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic < em > NRG1 < /em > fusions

CONCLUSION: Seribantumab treatment blocked activation of the four ERBB family members and of downstream signaling, leading to inhibition of NRG1 fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models.PMID:33824166 | DOI:10.1158/1078-0432.CCR-20-3605

Source: Clinical Cancer Research - April 7, 2021 Category: Cancer & Oncology Authors: Igor Odintsov Allan Jw Lui Whitney J Sisso Eric G Gladstone Zebing Liu Lukas Delasos Renate I Kurth Exequiel M Sisso Morana Vojnic Inna Khodos Marissa Mattar Elisa de Stanchina Shawn M Leland Marc Ladanyi Romel Somwar Source Type: research